Spero Therapeutics, a clinical-stage biopharmaceutical company, will announce its financial results for Q2 ended June 30, 2026, on August 12 after market close. The company will also provide a business and pipeline update during a conference call and webcast. Spero is advancing SP001, a next-generation immunology drug candidate targeting IgG4-related disease and other immune conditions. Investors can access the live webcast via the company’s website or by phone.
American Eagle Outfitters reported strong Q2 results with earnings per share of $0.79, far exceeding the $0.22 estimate, and revenue of $1.38 billion, slightly above expectations. The growth was driven by a 25% revenue increase from its Aerie and OFF...
AeroVironment reported a strong quarterly earnings per share (EPS) of $0.59, well above analyst expectations of $0.22, showing solid profitability. However, its revenue of $329.06 million fell short of the estimated $451.95 million, reflecting mixed ...
Kuehn Law is investigating Picard Medical Inc. for possible breaches of fiduciary duty by its officers and directors. The lawsuit alleges that insiders engaged in a fraudulent stock promotion scheme using social media misinformation and fake financia...
Caleres reported a strong Q3 2026 earnings per share (EPS) of $0.47, surpassing analyst expectations by 27%, signaling improved profitability. However, its revenue of $695.45 million slightly missed estimates despite a 5.6% year-over-year increase, d...
Listen Labs, a startup using voice AI for customer interviews, walked away from a signed $125 million Series C funding round led by Menlo Ventures. The funding likely fell through due to ongoing acquisition talks with Salesforce, which is considering...
